Axa S.A. Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

AXA S.A. bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 89,482 shares of the company's stock, valued at approximately $1,686,000. AXA S.A. owned 0.19% of Pacira BioSciences at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in PCRX. PDT Partners LLC lifted its holdings in Pacira BioSciences by 7.9% in the fourth quarter. PDT Partners LLC now owns 248,607 shares of the company's stock valued at $4,684,000 after acquiring an additional 18,130 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Pacira BioSciences by 30.8% in the 4th quarter. Northern Trust Corp now owns 616,891 shares of the company's stock valued at $11,622,000 after purchasing an additional 145,205 shares during the last quarter. Tudor Investment Corp ET AL purchased a new position in shares of Pacira BioSciences during the 4th quarter worth $427,000. State of Tennessee Department of Treasury increased its position in shares of Pacira BioSciences by 14.2% during the 4th quarter. State of Tennessee Department of Treasury now owns 26,180 shares of the company's stock worth $493,000 after purchasing an additional 3,264 shares during the last quarter. Finally, MetLife Investment Management LLC raised its holdings in Pacira BioSciences by 5.6% in the 4th quarter. MetLife Investment Management LLC now owns 27,883 shares of the company's stock valued at $525,000 after buying an additional 1,471 shares during the period. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Stock Up 0.8 %

Shares of PCRX traded up $0.21 during midday trading on Friday, hitting $25.12. The company had a trading volume of 2,242,337 shares, compared to its average volume of 963,506. Pacira BioSciences, Inc. has a 1 year low of $11.16 and a 1 year high of $31.67. The firm has a market capitalization of $1.16 billion, a P/E ratio of -12.37 and a beta of 0.56. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The company's 50-day simple moving average is $24.73 and its 200-day simple moving average is $22.13.

Wall Street Analysts Forecast Growth

PCRX has been the subject of several research analyst reports. Barclays increased their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and lifted their target price for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Needham & Company LLC decreased their price target on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research note on Friday. HC Wainwright raised their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Pacira BioSciences presently has a consensus rating of "Hold" and a consensus target price of $26.44.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.